60P Real-world report of late presenting adverse events and its management strategies in patients with RET-altered tumours on selective RET inhibitors

Selective RET tyrosine kinase inhibitors (TKIs) have become standard treatment for advanced/metastatic RET-altered solid tumours. Efficacy was seen in LIBRETTO-001 and ARROW. Late presenting adverse events (LPAEs) are not well described. Real-world data (RWD) can be utilized on these issues not addressed in clinical trial. We presented RWD on resistance mechanisms and post progression treatment outcomes at an earlier conference (Cheung et al. ESMO 2025). Here, we report in detail LPAEs and its management strategies.